drugset / Trial / NCT02430181
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
RandomizedParallel-groupOpen-labelTreatment
Summary
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
Timeline
- Start
- 2014-11
- Primary completion
- 2015-09
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lonafarnib | Small molecule | 100 mg | — |
| Subject | Lonafarnib | Small molecule | 200 mg | — |
| Subject | Lonafarnib | Small molecule | 300 mg | — |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |